Paratek’s antibiotic succeeds in Phase IIb lung disease trial
The Phase IIb trial of Novo-owned biotech’s Nuzyra showed at least 50% improvement in patients with symptoms of nontuberculous mycobacterial (NTM) pulmonary disease.
11 November 2024
11 November 2024
The Phase IIb trial of Novo-owned biotech’s Nuzyra showed at least 50% improvement in patients with symptoms of nontuberculous mycobacterial (NTM) pulmonary disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.